Pb2180 Experience Vrd‐pace‐like Regimen in Patients With Primary Refractory Myeloma for Peripheral Stem Cell Mobilization

Abstract

Background: In the era of novel anti-myeloma agents and monoclonal antibodies (daratumumab) and due to their high cost, earlier low cost regimens (VAD or CyBorD) may be used. Aims: to compare outcome of treatment of CyBorD versus VAD regimens in multiple myeloma Methods: This cohort study included 89 MM patients treated at National Cancer Institute (NCI), Cairo, Egypt from January 2011 to December 2015. All patients were evaluated clinically and laboratory for different responses with either lines of treatment (VAD versus CyBorD), and correlated with different survival parameters; progression free (PFS), disease free (DFS), and overall survival (OS), and clinico-pathologic factors. Results: The median age of patients was 54 years (32-76), with male predominance (male to female ratio 1.87:1). The most common presenting symptoms were bony pains (44.9%) followed by bony masses (22.5%), fractures